As these clinical trials with limited/negative results were performed in moderate to severe AD patients, the lack of efficacy of Tezepelumab could be at least partially explained by the context-dependent implication of TSLP in allergic skin inflammation and sensitization in these patients. The gene discussed is TSLP; the disease is Alzheimer disease.